Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI

Intra-Cellular Therapies Stock Analysis & Ratings

Intra-Cellular Therapies Stock Analysis Overview

Smart Score
8
Outperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Intra-Cellular Therapies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

ITCI

ITCI Stock Stats

Previous Close$38.74
Open$39
Bid38 x 100
Ask39.25 x 1000
Today’s Range$38.58 - $40.35
52-Week Range$28.40 - $55.20
Volume747.13K
Average Volume803.17K
Market Cap$3.59B
Beta1.14
P/E Ratio-12.1
EPS-3.20
Earnings DateMar 02, 2022

Company Description

Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Sharon Mates
Employees
383
Website
www.intracellulartherapies.com
ISIN
US46116X1019
Address
430 East 29th Street, New York, NY, 10016, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

ITCI FAQ

What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $28.40 and its highest was $55.20 in the past 12 months.
    What is Intra-Cellular Therapies’s market cap?
    Intra-Cellular Therapies’s market cap is $3.59B.
      What is Intra-Cellular Therapies’s price target?
      The average price target for Intra-Cellular Therapies is $62.71. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $88.00 ,the lowest forecast is $40.00. The average price target represents 61.33% Increase from the current price of $38.87.
        What do analysts say about Intra-Cellular Therapies?
        Intra-Cellular Therapies’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
          When is Intra-Cellular Therapies’s upcoming earnings report date?
          Intra-Cellular Therapies’s upcoming earnings report date is Mar 02, 2022 which is in 41 days.
            How were Intra-Cellular Therapies’s earnings last quarter?
            Intra-Cellular Therapies released its earnings results on Nov 09, 2021. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.925 by -$0.025.
              Is Intra-Cellular Therapies overvalued?
              According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
                Does Intra-Cellular Therapies pay dividends?
                Intra-Cellular Therapies does not currently pay dividends.
                What is Intra-Cellular Therapies’s EPS estimate?
                Intra-Cellular Therapies’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Intra-Cellular Therapies have?
                Intra-Cellular Therapies has 92,420,000 shares outstanding.
                  What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
                  Intra-Cellular Therapies reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.925. Following the earnings report the stock price went down -2.736%.
                    Which hedge fund is a major shareholder of Intra-Cellular Therapies?
                    Among the largest hedge funds holding Intra-Cellular Therapies’s share is Hussman Strategic Advisors Inc. It holds Intra-Cellular Therapies’s shares valued at N/A.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis